ArticleInfection and drug resistance2026
Colistin Therapy for Urinary Tract Infections Due to Multidrug-Resistant Bacteria: Experience at a Tertiary Academic Medical Center.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does a Loading Dose Improve Outcomes? Colistin Therapy for Urinary Tract Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) present increasing therapeutic challenges, especially in regions with limited access to novel β-lactam/β-lactamase inhibitors. Colistin remains a salvage therapy in such cases; however, data describing its real-world efficacy and nephrotoxicity in urinary infections are limited. Methods: We conducted a retrospective cohort study of adult patients who received intravenous colistin (colistimethate sodium) for culture-confirmed UTIs at a tertiary academic medical center in Riyadh, Saudi Arabia. The primary outcome was colistin-induced acute kidney injury (AKI), defined as an increase in serum creatinine of ≥26 µmol/L from baseline per the AKIN creatinine criterion. Secondary outcomes included microbiologic failure, clinical failure, and in-hospital mortality. Multivariable logistic regression was used to identify independent predictors of AKI. Results: Among 102 patients, the median age was 80 years (IQR, 72-84), and 46% were male. Conclusion: In this cohort of patients with MDR-GNB UTIs, intravenous colistin was associated with favorable clinical and microbiological outcomes. The observed incidence of AKI was lower than previously reported in the literature, though this should be interpreted cautiously given the small number of events and the high prevalence of baseline renal impairment and nephrotoxic co-exposures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.